Author

I. W. Vock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

A. J. L. Huldin· 1 shared A. Mapp· 1 shared J. A. Schofield· 1 shared J. T. Zimmer· 1 shared L. Kiefer· 1 shared M. D. Simon· 1 shared M. H. Moon· 1 shared M. J. Beyersdorf· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. J. L. Huldin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Improving the study of RNA dynamics through advances in RNA-seq with metabolic labeling and nucleotide-recoding chemistry

J. T. Zimmer, I. W. Vock, J. A. Schofield, L. Kiefer, M. H. Moon, M. D. Simon

This paper identifies and mitigates dropout in RNA metabolic labeling and NR-seq experiments through optimized protocols and improved alignment pipelines.

bioRxiv · May 24, 2023 · PreprintBiochemistry

A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb

S. T. Joy, M. J. Henley, S. N. De Salle, M. J. Beyersdorf, I. W. Vock, A. J. L. Huldin, A. Mapp

This paper develops a dual-site inhibitor, MybLL-tide, that selectively targets the CBP/p300 KIX domain, inhibiting Myb-dependent gene expression in AML cells.

bioRxiv · Apr 28, 2021Biochemistry